Friday, June 11, 2021 2:40:53 PM
Grade 1 CRS was reported in four patients and Grade 2 CRS in one. No immune effector cell-associated neurotoxicity syndrome of any grade was observed. At a median follow-up of six months (range 4.0-8.1), eight of nine patients were disease free, with one relapse at month six, but was rescued with radiotherapy. One died of a Cov infection at month 5.6 whilst in complete metabolic response.
Also, twenty patients in Cohort A with R/R aALL had received obe-cel. The therapy was well tolerated, with no patients experiencing Grade 3 or higher CRS. Three patients, all of whom had high leukaemia burden (over 50% blasts), experienced Grade 3 ICANS that resolved swiftly with steroids.
Of the twenty patients evaluable for efficacy, seventeen achieved minimum residual disease negative complete response at one month. Most notably, the durability of remissions is highly encouraging. Across all treated patients, event free survival at twelve months and twenty-four months is 50.2% with the median not being reached.
The call https://edge.media-server.com/mmc/p/wbmik6fg
Slides https://autolus.gcs-web.com/static-files/b4ca8abe-8b75-4690-a9fd-2680e161f0f5
Recent AUTL News
- Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO • GlobeNewswire Inc. • 04/24/2024 02:00:00 PM
- Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 • GlobeNewswire Inc. • 04/23/2024 11:00:00 AM
- Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Autolus Therapeutics Announces Changes to its Board of Directors • GlobeNewswire Inc. • 04/01/2024 11:00:00 AM
- Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates • GlobeNewswire Inc. • 03/14/2024 11:00:00 AM
- Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site • GlobeNewswire Inc. • 03/12/2024 11:00:00 AM
- Autolus Therapeutics announces publication in Blood Cancer Journal • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024 • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/23/2024 10:28:32 PM
- Autolus Therapeutics announces publication in Nature Communications • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/21/2024 10:01:33 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:37:20 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/09/2024 10:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:17:55 PM
- Autolus Announces Pricing of Underwritten Offering • GlobeNewswire Inc. • 02/08/2024 12:00:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 11:06:00 AM
- BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs • GlobeNewswire Inc. • 02/08/2024 10:45:00 AM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/08/2024 03:00:28 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/31/2024 09:10:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 06:02:13 PM
- Autolus Therapeutics announces publication in ACS Chemical Biology • GlobeNewswire Inc. • 01/23/2024 12:00:00 PM
- Autolus Therapeutics Gets BLA Acceptance for Obecabtagene Autoleucel • Dow Jones News • 01/22/2024 12:54:00 PM
- Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL) • GlobeNewswire Inc. • 01/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 08:12:17 PM
- Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors • GlobeNewswire Inc. • 01/10/2024 12:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM